Odefsey is a fixed-dose tablet combining 25mg of rilpivirine, 200mg of emtricitabine and 25mg of tenofovir alafenamide (TAF). It is manufactured by Gilead Sciences.

Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI), emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI), and tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor (NtRTI). These drugs reduce the amount of HIV in the body and prevent the development of AIDS-defining illnesses.

The standard dose of Odefsey is one grey tablet once day with food. Odefsey is approved as initial treatment for people with a viral load below 100,000 copies/ml and for people switching from another drug combination with an undetectable viral load regardless of their viral load before treatment.

Odefsey received marketing approval in the United States in March 2016 and in the European Union in June 2016.

For more information on Odefsey’s component drugs, including drug interactions, side-effects and resistance, see rilpivirine, emtricitabine and tenofovir.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.